Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Featured trial
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

myelodysplastic syndromes
anemia studies
myelodysplastic syndrome (mds)
aplastic anemia
anemia
  • 75 views
  • 22 Dec, 2020
  • 1 location
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an

rad001
vegf
everolimus
cancer
mtor inhibitor
  • 16 views
  • 30 Jun, 2022
  • 10 locations
mTOR as Mediator of Insulin Sensitivity Study

subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.

Accepts healthy volunteers
  • 0 views
  • 11 Jul, 2022
  • 1 location
A Study of Monepantel in Individuals With Motor Neurone Disease

disease progression in certain preclinical models of ALS/MND and is suggested to provide synergy with the ALS/MND standard-of-care drug, riluzole. An alternative mTOR inhibitor, rapamycin, is currently

  • 0 views
  • 15 Jul, 2022
  • 1 location
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection (STARR)

missing self on their graft responsible for a NK-mediated rejection will be established prospectively. An mTOR inhibitor will be introduced in these patients for 6 months in association with a calcineurin

Accepts healthy volunteers
  • 0 views
  • 25 May, 2022
Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

reticulocyte count
immunosuppressant
immunosuppression
sirolimus
neutrophil count
  • 14 views
  • 25 Jul, 2022
  • 1 location
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

MRI
131i-mibg
graft-versus-host disease
anti-cancer agents
gliomas
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension

animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

primary pulmonary hypertension
pulmonary arterial hypertension
congenital heart defects
pulmonary function test
left ventricular end-diastolic pressure
  • 27 views
  • 26 Jan, 2022
  • 6 locations
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient

kidney transplant recipient. However, there are evidences from retrospective and prospective studies showed that leflunomide and mTOR inhibitor such as everolimus or sirolimus have positive outcomes in

  • 0 views
  • 11 May, 2021
  • 1 location
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.

lung cancer
metastasis
ct scan
cancer
gedatolisib
  • 188 views
  • 23 Mar, 2022
  • 1 location